Identification of traditional Japanese Kampo medicines and crude drugs that upregulate brain‑derived neurotrophic factor in human peripheral cells

Abstract

The neurotrophic hypothesis of depression, which suggests that decreased hippocampal brain‑derived neurotrophic factor (BDNF) levels cause depression, has become increasingly popular. BDNF, a member of the neurotrophin family,\r\npromotes neuronal differentiation and survival. BDNF is synthesized in various peripheral tissues, as well as in the brain. Considering that peripheral BDNF can be transported into the brain across the blood‑brain barrier, substances with the ability to upregulate BDNF activity in peripheral tissues may be useful in the management of depression. Previously, we demonstrated that the human kidney adenocarcinoma cell line ACHN produces BDNF; hence, this cell line was employed for screening upregulators of peripheral BDNF. Here, we aimed to identify Kampo (traditional Japanese) medicines and their crude drug components that upregulate BDNF levels using ACHN cells. Chotosan, Hochuekkito, Kososan, and Ninjinyoeito, Kampo medicines used in treating psychiatric disorders, increased BDNF levels in the culture media of ACHN cells.\r\nFurthermore, Chinpi (Citrus unshiu peel), a crude drug contained in these four Kampo medicines, as well as Onji (Polygala tenuifolia root), and Saiko (Bupleurum falcatum root) elevated BDNF levels in ACHN cells. Chinpi, showing strong BDNF elevating effect, increased BDNF mRNA expression. Inhibitors of protein kinase B, mitogen‑activated protein kinase kinase, and cAMP‑dependent protein kinase, involved in the transcription of BDNF, attenuated Chinpi‑induced BDNF elevation. Our results suggest that Chinpi and Kampo medicines containing Chinpi can promote the production of BDNF in peripheral tissues, potentially alleviating depression symptoms.